Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 3/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31044635 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL10028665 | 0.92 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL30093157 | 0.88 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL16627431 | 0.87 | CHRNB2 (0.77) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL22928701 | 0.86 | CHRNB2 (0.75) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL21278464 | 0.85 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL8348697 | 0.85 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL6132943 | 0.85 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL10509238 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 | |
| SCHEMBL12197592 | 0.84 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA7ALDH1A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114428-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | NORTHWEST UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| WO-2021101919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-27 | — | — | WO | disclosed |
| EP-3145929-B1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-13 | — | — | EP | disclosed |
| EP-3309146-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9708305-B2 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases | UNIVERSITé LAVAL (CA) | 2017-07-18 | — | — | US | disclosed |
| US-20100016956-A1 | Triazole compounds and methods of making and using the same | BioVersys AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016956-A1 | Triazole compounds and methods of making and using the same | BioVersys AG (CH) | 2010-01-21 | — | — | US | disclosed |
| WO-2008143729-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008106226-A2 | MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1456206-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053970-A1 | AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016956-A1 | Triazole compounds and methods of making and using the same | IL33, PROKR1, PGC | CHRNB2 4851/4885CHRNA4 4785/4885CHRNA7 4560/4885 |
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CHRNB2 336/4885CHRNA4 230/4885CHRNA7 238/4885 |
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | VIP, PREP, ACE | CHRNB2 4354/4885CHRNA4 4638/4885CHRNA7 4408/4885 |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | CHRNB2 4807/4885CHRNA4 4750/4885CHRNA7 4537/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | CHRNB2 645/4885CHRNA4 434/4885CHRNA7 486/4885 |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, ABHD16A, CETP | CHRNB2 4737/4885CHRNA4 4719/4885CHRNA7 4507/4885 |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | VIP, PREP, ACE | CHRNB2 4354/4885CHRNA4 4638/4885CHRNA7 4408/4885 |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | CHRNB2 2779/4885CHRNA4 2092/4885CHRNA7 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.